Dr. Wenli Gao, MD - Danbury, CT ...

Dr. Wenli GaO

Claim this profile

Danbury Hospital

Studies Breast Cancer
Studies Breast cancer
8 reported clinical trials
20 drugs studied

Area of expertise

1

Breast Cancer

Wenli GaO has run 4 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
ER negative
PR negative
2

Breast Cancer

Wenli GaO has run 4 trials for Breast cancer. Some of their research focus areas include:

HER2 positive
ER negative
PR negative

Affiliated Hospitals

Image of trial facility.

Danbury Hospital

Clinical Trials Wenli GaO is currently running

Image of trial facility.

Herceptin Hylecta or Phesgo + Chemotherapy

for Uterine Cancer

This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.

Recruiting

2 awards

Phase 3

Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

More about Wenli GaO

Clinical Trial Related

7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Wenli GaO has experience with

  • Carboplatin
  • Atezolizumab
  • Trastuzumab
  • Paclitaxel
  • Pertuzumab
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Wenli GaO specialize in?

Is Wenli GaO currently recruiting for clinical trials?

Are there any treatments that Wenli GaO has studied deeply?

What is the best way to schedule an appointment with Wenli GaO?

What is the office address of Wenli GaO?

Is there any support for travel costs?